Joel K. Yisraeli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Joel K. Yisraeli has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
Froma Oberman
Department of Developmental Biology and Cancer Research, Institute for Medical Research – Israel-Canada, Hebrew University Hadassah Medical School, Jerusalem, Israel
12 shared publicationsKarina Yaniv
Department of Anatomy and Cell Biology, Hebrew University - Hadassah Medical School, POB 12272, 91120 Jerusalem, Israel
5 shared publicationsGilad Vainer
Department of Pathology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
4 shared publicationsAbraham Fainsod
Department of Cellular Biochemistry and Human Genetics, Hebrew University– Hadassah Medical School, POB 12272, 91120 Jerusalem, Israel
3 shared publicationsAmandeep Singh
The Pennsylvania State University College of Medicine, Department of Molecular and Precision Medicine, Penn State Cancer Institute, Hershey, USA
3 shared publicationsArun K. Sharma
The Pennsylvania State University College of Medicine, Department of Molecular and Precision Medicine, Penn State Cancer Institute, Hershey, USA
3 shared publications
Latest Publications
- Open Access
Analysis of genes co-evolved with Igf2bp RNA-Binding Proteins provides insights into post-transcriptional regulatory networks
The Insulin-like growth factor 2 mRNA-binding protein (Igf2bp) family comprises three paralogous RNA-binding proteins—Igf2bp1, Igf2bp2, and Igf2bp3—that are highly conserved across chordates. Originally identified through diverse experimental screens probing intracellular RNA localization, RNA stability, and translational control, Igf2bps were initially studied in isolation from one another and within narrowly defined molecular contexts. Over time, it has become clear that these proteins act as multifunctional regulators of RNA metabolism and participate in a broad range of developmental and pathological processes. Here, we review the discovery, molecular functions, and biological roles of Igf2bp proteins, with particular emphasis on their conserved involvement in nervous system development and their reactivation in cancer. Given the emerging appreciation of the connection between genes involved in neural development and tumorigenesis, we thought it might be informative to perform a comparative evolutionary analysis to identify genes that coevolved with Igf2bp paralogs. These coevolved genes are strongly enriched for functions in axon guidance and neurogenesis, but also substantially overlap with experimentally defined Igf2bp1 RNA targets in lung adenocarcinoma (LUAD) cells. Notably, many of these genes are downregulated upon pharmacological inhibition of Igf2bp1 RNA binding. In this speculative review, we propose a model in which Igf2bp proteins evolved as coordinators of post-transcriptional gene regulation in the developing nervous system and were later co-opted in cancer to stabilize and coordinate oncogenic gene expression programs.
Open AccessAnalysis of genes co-evolved with Igf2bp RNA-Binding Proteins provides insights into post-transcriptional regulatory networks
The Insulin-like growth factor 2 mRNA-binding protein (Igf2bp) family comprises three paralogous RNA-binding proteins—Igf2bp1, Igf2bp2, and Igf2bp3—that are highly conserved across chordates. Originally identified through diverse experimental screens probing intracellular RNA localization, RNA stability, and translational control, Igf2bps were initially studied in isolation from one another and within narrowly defined molecular contexts. Over time, it has become clear that these proteins act as multifunctional regulators of RNA metabolism and participate in a broad range of developmental and pathological processes. Here, we review the discovery, molecular functions, and biological roles of Igf2bp proteins, with particular emphasis on their conserved involvement in nervous system development and their reactivation in cancer. Given the emerging appreciation of the connection between genes involved in neural development and tumorigenesis, we thought it might be informative to perform a comparative evolutionary analysis to identify genes that coevolved with Igf2bp paralogs. These coevolved genes are strongly enriched for functions in axon guidance and neurogenesis, but also substantially overlap with experimentally defined Igf2bp1 RNA targets in lung adenocarcinoma (LUAD) cells. Notably, many of these genes are downregulated upon pharmacological inhibition of Igf2bp1 RNA binding. In this speculative review, we propose a model in which Igf2bp proteins evolved as coordinators of post-transcriptional gene regulation in the developing nervous system and were later co-opted in cancer to stabilize and coordinate oncogenic gene expression programs.
- Open Access
- 8 July 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (35) , 3239-3254
AVJ16 inhibits lung carcinoma by targeting IGF2BP1
IGF2BP1 is an oncofoetal RNA binding protein (RBP) expressed in many tumors. Interest has focused of late on the role of RBPs in cancer, although their mechanism of action is not always well understood. Using a newly described small molecule inhibitor of IGF2BP1, termed AVJ16, we have analyzed the effects of this inhibition on RNA binding, RNA expression, and protein expression. AVJ16 treatment downregulates RNAs encoding members of several pro-oncogenic signaling pathways, including Hedgehog, Wnt, and PI3K-Akt, and there is a strong correlation between IGF2BP1 RNA binding, RNA expression, and protein expression. At the cellular level, colony formation, invasion, and spheroid growth are all strongly reduced by exposure to AVJ16, while apoptosis and cell death are enhanced. All of these effects are limited to cells expressing IGF2BP1. In syngeneic LUAD xenografts in mice, IP injection of AVJ16 prevents tumor growth, and incubation with AVJ16 induces cell death in human organoids derived from IGF2BP1-expressing LUADs but not from healthy lung tissue. These results demonstrate that AVJ16 is a promising candidate for targeted therapy directed against tumors expressing IGF2BP1.
- 8 July 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (35) , 3239-3254
Open AccessAVJ16 inhibits lung carcinoma by targeting IGF2BP1
IGF2BP1 is an oncofoetal RNA binding protein (RBP) expressed in many tumors. Interest has focused of late on the role of RBPs in cancer, although their mechanism of action is not always well understood. Using a newly described small molecule inhibitor of IGF2BP1, termed AVJ16, we have analyzed the effects of this inhibition on RNA binding, RNA expression, and protein expression. AVJ16 treatment downregulates RNAs encoding members of several pro-oncogenic signaling pathways, including Hedgehog, Wnt, and PI3K-Akt, and there is a strong correlation between IGF2BP1 RNA binding, RNA expression, and protein expression. At the cellular level, colony formation, invasion, and spheroid growth are all strongly reduced by exposure to AVJ16, while apoptosis and cell death are enhanced. All of these effects are limited to cells expressing IGF2BP1. In syngeneic LUAD xenografts in mice, IP injection of AVJ16 prevents tumor growth, and incubation with AVJ16 induces cell death in human organoids derived from IGF2BP1-expressing LUADs but not from healthy lung tissue. These results demonstrate that AVJ16 is a promising candidate for targeted therapy directed against tumors expressing IGF2BP1.
- Open Access
AVJ16 inhibits the RNA binding protein IGF2BP1 in lung adenocarcinomas and prevents tumor growth in mice
IGF2BP1 is an oncofoetal RNA binding protein that is expressed in many tumors. We have recently described a small molecule inhibitor of IGF2BP1, termed AVJ16, that prevents binding of the protein to its RNA targets by directly associating with the protein. Here, using a multi-omics approach, we have analyzed the effects of this inhibition on RNA binding, RNA expression, and protein expression. AVJ16 treatment downregulates RNAs encoding members of several pro-oncogenic signaling pathways, including Hedgehog, Wnt, and PI3K-Akt, and there is a strong correlation between IGF2BP1 RNA binding, RNA expression, and protein expression. AVJ16 treatment of lung adenocarcinoma (LUAD) cells in culture causes a strong reduction in proliferation, colony formation, invasion, and spheroid growth while enhancing apoptosis and cell death. All of these effects are limited to cells expressing IGF2BP1. LUAD cells treated with AVJ16 show a pronounced reduction in vital dye efflux, often correlated with enhanced chemosensitivity. In syngeneic LUAD xenografts in mice, IP injection of AVJ16 prevents tumor growth, and incubation with AVJ16 induces cell death in human organoids derived from IGF2BP1-expressing LUADs but not from healthy lung tissue. These results suggest that AVJ16 is a promising candidate for mono- and/or adjuvant therapy directed against tumors expressing IGF2BP1.
Open AccessAVJ16 inhibits the RNA binding protein IGF2BP1 in lung adenocarcinomas and prevents tumor growth in mice
IGF2BP1 is an oncofoetal RNA binding protein that is expressed in many tumors. We have recently described a small molecule inhibitor of IGF2BP1, termed AVJ16, that prevents binding of the protein to its RNA targets by directly associating with the protein. Here, using a multi-omics approach, we have analyzed the effects of this inhibition on RNA binding, RNA expression, and protein expression. AVJ16 treatment downregulates RNAs encoding members of several pro-oncogenic signaling pathways, including Hedgehog, Wnt, and PI3K-Akt, and there is a strong correlation between IGF2BP1 RNA binding, RNA expression, and protein expression. AVJ16 treatment of lung adenocarcinoma (LUAD) cells in culture causes a strong reduction in proliferation, colony formation, invasion, and spheroid growth while enhancing apoptosis and cell death. All of these effects are limited to cells expressing IGF2BP1. LUAD cells treated with AVJ16 show a pronounced reduction in vital dye efflux, often correlated with enhanced chemosensitivity. In syngeneic LUAD xenografts in mice, IP injection of AVJ16 prevents tumor growth, and incubation with AVJ16 induces cell death in human organoids derived from IGF2BP1-expressing LUADs but not from healthy lung tissue. These results suggest that AVJ16 is a promising candidate for mono- and/or adjuvant therapy directed against tumors expressing IGF2BP1.
- Open Access
- 5 December 2023
- Published by Springer Nature in Communications Biology
- Vol. 6 (1) , 1-14
RNA binding protein IGF2BP2 expression is induced by stress in the heart and mediates dilated cardiomyopathy
The IGF2BP family of RNA binding proteins consists of three paralogs that regulate intracellular RNA localization, RNA stability, and translational control. Although IGF2BP1 and 3 are oncofetal proteins, IGF2BP2 expression is maintained in many tissues, including the heart, into adulthood. IGF2BP2 is upregulated in cardiomyocytes during cardiac stress and remodeling and returns to normal levels in recovering hearts. We wondered whether IGF2BP2 might play an adaptive role during cardiac stress and recovery. Enhanced expression of an IGF2BP2 transgene in a conditional, inducible mouse line leads to dilated cardiomyopathy (DCM) and death within 3-4 weeks in newborn or adult hearts. Downregulation of the transgene after 2 weeks, however, rescues these mice, with complete recovery by 12 weeks. Hearts overexpressing IGF2BP2 downregulate sarcomeric and mitochondrial proteins and have fragmented mitochondria and elongated, thinner sarcomeres. IGF2BP2 is also upregulated in DCM or myocardial infarction patients. These results suggest that IGF2BP2 may be an attractive target for therapeutic intervention in cardiomyopathies.
- 5 December 2023
- Published by Springer Nature in Communications Biology
- Vol. 6 (1) , 1-14
Open AccessRNA binding protein IGF2BP2 expression is induced by stress in the heart and mediates dilated cardiomyopathy
The IGF2BP family of RNA binding proteins consists of three paralogs that regulate intracellular RNA localization, RNA stability, and translational control. Although IGF2BP1 and 3 are oncofetal proteins, IGF2BP2 expression is maintained in many tissues, including the heart, into adulthood. IGF2BP2 is upregulated in cardiomyocytes during cardiac stress and remodeling and returns to normal levels in recovering hearts. We wondered whether IGF2BP2 might play an adaptive role during cardiac stress and recovery. Enhanced expression of an IGF2BP2 transgene in a conditional, inducible mouse line leads to dilated cardiomyopathy (DCM) and death within 3-4 weeks in newborn or adult hearts. Downregulation of the transgene after 2 weeks, however, rescues these mice, with complete recovery by 12 weeks. Hearts overexpressing IGF2BP2 downregulate sarcomeric and mitochondrial proteins and have fragmented mitochondria and elongated, thinner sarcomeres. IGF2BP2 is also upregulated in DCM or myocardial infarction patients. These results suggest that IGF2BP2 may be an attractive target for therapeutic intervention in cardiomyopathies.
- Open Access
IGF2BP2 is Induced by Stress in the Heart and Mediates Dilated Cardiomyopathy
The IGF2BP family of RNA binding proteins consists of three paralogs that regulate intracellular RNA localization, RNA stability, and translational control. Although IGF2BP1 and 3 are oncofetal proteins, IGF2BP2 expression is maintained in many tissues, including the heart, into adulthood. Previous studies indicated that IGF2BP2 is upregulated in cardiomyocytes during cardiac stress and remodelling and returns to normal levels in recovering hearts. These results raise the possibility that IGF2BP2 might play an adaptive role during cardiac stress and recovery. Using a conditional, inducible transgenic mouse line, we found that enhanced expression of an IGF2BP2 transgene in newborn or adult hearts leads to dilated cardiomyopathy (DCM) and death within 3-4 weeks. Downregulation of the transgene after 2 weeks, however, rescues these mice, with complete recovery by 12 weeks. Hearts overexpressing IGF2BP2 downregulate sarcomeric and mitochondrial proteins and have fragmented mitochondria and elongated, thinner sarcomeres. Consistent with these results, IGF2BP2 is upregulated in patients with DCM or after myocardial infarction. These results suggest that IGF2BP2 may be an attractive target for therapeutic intervention in DCM.
Open AccessIGF2BP2 is Induced by Stress in the Heart and Mediates Dilated Cardiomyopathy
The IGF2BP family of RNA binding proteins consists of three paralogs that regulate intracellular RNA localization, RNA stability, and translational control. Although IGF2BP1 and 3 are oncofetal proteins, IGF2BP2 expression is maintained in many tissues, including the heart, into adulthood. Previous studies indicated that IGF2BP2 is upregulated in cardiomyocytes during cardiac stress and remodelling and returns to normal levels in recovering hearts. These results raise the possibility that IGF2BP2 might play an adaptive role during cardiac stress and recovery. Using a conditional, inducible transgenic mouse line, we found that enhanced expression of an IGF2BP2 transgene in newborn or adult hearts leads to dilated cardiomyopathy (DCM) and death within 3-4 weeks. Downregulation of the transgene after 2 weeks, however, rescues these mice, with complete recovery by 12 weeks. Hearts overexpressing IGF2BP2 downregulate sarcomeric and mitochondrial proteins and have fragmented mitochondria and elongated, thinner sarcomeres. Consistent with these results, IGF2BP2 is upregulated in patients with DCM or after myocardial infarction. These results suggest that IGF2BP2 may be an attractive target for therapeutic intervention in DCM.
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 5446
Abstract 5446: Discovery of a novel IGF2BP1 inhibitor, based on lead optimization through structure-activity relationship studies, as metastasis-specific therapeutic agent
IGF2BP1 is a multifunctional RNA-binding protein that regulates the stability, localization and translation of its mRNA targets. High levels of IGF2BP1 expression have been shown to be associated with poor prognosis in patients with variety of cancer types. Given the correlation between elevated IGF2BP1 expression and poor clinical outcomes, the specific activation of IGF2BP paralogs in a wide variety of cancers, and the effectiveness of preventing metastasis in animal models by reducing IGF2BP1 activity, therapies directed at inhibiting IGF2BP1 function constitute a potentially powerful approach for fighting cancer. In addition, IGF2BP1’s pleiotropic effect on multiple pro-tumorigenic and pro-metastatic pathways makes it a promising target, as this may avoid the development of resistance, associated with targeted agents in general. Furthermore, specific inhibitors of IGF2BP1 would be expected to have minimal side effects since; i) IGF2BP1 is expressed at very low levels in normal adult tissues, and ii) adult mice with an inducible whole-mouse knockout of IGF2BP1 are healthy. To identify an efficient IGF2BP1 inhibitor, a fluorescent polarization (FP)-based high throughput screen of over 100,000 small molecules was performed, and the most promising candidates were further validated in an array of in vitro and cell-based assays leading to the identification a lead compound, “7773,” that selectively inhibited IGF2BP1 RNA binding and a variety of its cellular functions. To further optimize ‘7773’ and create more selective, effective and safe small-molecule inhibitors of IGF2BP1 that could be developed clinically as cancer therapeutics, we conducted a SAR study based on the lead ‘7773’ structure. Novel 27 compounds were designed and synthesized and evaluated for IGF2BP1 inhibition using our novel cell-based split-luciferase assay, which led to the identification of 6 compounds that performed similar or better than ‘7773’. Cell-based wound healing assay revealed that one of these selected compounds, AVJ16, was especially (>14 times than “7773”) effective in inhibiting cell migration in H1299 cell line that express high levels of endogenous IGF2BP1, but not in LKR-M cells that express very low levels of IGF2BP1. The specificity of AVJ16 was further confirmed in LKR-M cells that ectopically express IGF2BP1 - these cells become sensitive to AVJ16 upon overexpression of IGF2BP1 (but not GFP). Together our data provide strong evidence for AVJ16 to be effective and selective in inhibiting IGF2BP1 function by interfering with its ability to bind target RNAs. Citation Format: Amandeep Singh, Arun Sharma, Vladimir Spiegelman, Vikash Singh, Nadav Wallis, Omer Elimelech, Joel Yisraeli. Discovery of a novel IGF2BP1 inhibitor, based on lead optimization through structure-activity relationship studies, as metastasis-specific therapeutic agent [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5446.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 5446
Open AccessAbstract 5446: Discovery of a novel IGF2BP1 inhibitor, based on lead optimization through structure-activity relationship studies, as metastasis-specific therapeutic agent
IGF2BP1 is a multifunctional RNA-binding protein that regulates the stability, localization and translation of its mRNA targets. High levels of IGF2BP1 expression have been shown to be associated with poor prognosis in patients with variety of cancer types. Given the correlation between elevated IGF2BP1 expression and poor clinical outcomes, the specific activation of IGF2BP paralogs in a wide variety of cancers, and the effectiveness of preventing metastasis in animal models by reducing IGF2BP1 activity, therapies directed at inhibiting IGF2BP1 function constitute a potentially powerful approach for fighting cancer. In addition, IGF2BP1’s pleiotropic effect on multiple pro-tumorigenic and pro-metastatic pathways makes it a promising target, as this may avoid the development of resistance, associated with targeted agents in general. Furthermore, specific inhibitors of IGF2BP1 would be expected to have minimal side effects since; i) IGF2BP1 is expressed at very low levels in normal adult tissues, and ii) adult mice with an inducible whole-mouse knockout of IGF2BP1 are healthy. To identify an efficient IGF2BP1 inhibitor, a fluorescent polarization (FP)-based high throughput screen of over 100,000 small molecules was performed, and the most promising candidates were further validated in an array of in vitro and cell-based assays leading to the identification a lead compound, “7773,” that selectively inhibited IGF2BP1 RNA binding and a variety of its cellular functions. To further optimize ‘7773’ and create more selective, effective and safe small-molecule inhibitors of IGF2BP1 that could be developed clinically as cancer therapeutics, we conducted a SAR study based on the lead ‘7773’ structure. Novel 27 compounds were designed and synthesized and evaluated for IGF2BP1 inhibition using our novel cell-based split-luciferase assay, which led to the identification of 6 compounds that performed similar or better than ‘7773’. Cell-based wound healing assay revealed that one of these selected compounds, AVJ16, was especially (>14 times than “7773”) effective in inhibiting cell migration in H1299 cell line that express high levels of endogenous IGF2BP1, but not in LKR-M cells that express very low levels of IGF2BP1. The specificity of AVJ16 was further confirmed in LKR-M cells that ectopically express IGF2BP1 - these cells become sensitive to AVJ16 upon overexpression of IGF2BP1 (but not GFP). Together our data provide strong evidence for AVJ16 to be effective and selective in inhibiting IGF2BP1 function by interfering with its ability to bind target RNAs. Citation Format: Amandeep Singh, Arun Sharma, Vladimir Spiegelman, Vikash Singh, Nadav Wallis, Omer Elimelech, Joel Yisraeli. Discovery of a novel IGF2BP1 inhibitor, based on lead optimization through structure-activity relationship studies, as metastasis-specific therapeutic agent [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5446.
- Open Access
- 11 December 2021
- Published by Taylor & Francis in RNA Biology
- Vol. 19 (1) , 26-43
Small molecule inhibitor of Igf2bp1 represses Kras and a pro-oncogenic phenotype in cancer cells
Igf2bp1 is an oncofetal RNA binding protein whose expression in numerous types of cancers is associated with upregulation of key pro-oncogenic RNAs, poor prognosis, and reduced survival. Importantly, Igf2bp1 synergizes with mutations in Kras to enhance signalling and oncogenic activity, suggesting that molecules inhibiting Igf2bp1 could have therapeutic potential. Here, we isolate a small molecule that interacts with a hydrophobic surface at the boundary of Igf2bp1 KH3 and KH4 domains, and inhibits binding to Kras RNA. In cells, the compound reduces the level of Kras and other Igf2bp1 mRNA targets, lowers Kras protein, and inhibits downstream signalling, wound healing, and growth in soft agar, all in the absence of any toxicity. This work presents an avenue for improving the prognosis of Igf2bp1-expressing tumours in lung, and potentially other, cancer(s).
- 11 December 2021
- Published by Taylor & Francis in RNA Biology
- Vol. 19 (1) , 26-43
Open AccessSmall molecule inhibitor of Igf2bp1 represses Kras and a pro-oncogenic phenotype in cancer cells
Igf2bp1 is an oncofetal RNA binding protein whose expression in numerous types of cancers is associated with upregulation of key pro-oncogenic RNAs, poor prognosis, and reduced survival. Importantly, Igf2bp1 synergizes with mutations in Kras to enhance signalling and oncogenic activity, suggesting that molecules inhibiting Igf2bp1 could have therapeutic potential. Here, we isolate a small molecule that interacts with a hydrophobic surface at the boundary of Igf2bp1 KH3 and KH4 domains, and inhibits binding to Kras RNA. In cells, the compound reduces the level of Kras and other Igf2bp1 mRNA targets, lowers Kras protein, and inhibits downstream signalling, wound healing, and growth in soft agar, all in the absence of any toxicity. This work presents an avenue for improving the prognosis of Igf2bp1-expressing tumours in lung, and potentially other, cancer(s).
- 30 January 2019
- Published by Springer Nature in Oncogene
- Vol. 38 (21) , 4169-4181
VICKZ1 enhances tumor progression and metastasis in lung adenocarcinomas in mice
The VICKZ (Igf2bp) family of RNA binding proteins regulate RNA function at many levels, including intracellular RNA localization, RNA stability, and translational control. One or more of the three VICKZ paralogs are upregulated in many different types of cancers. Here, we show how VICKZ1 enhances, and dominant negative VICKZ1 inhibits, cell migration, growth in soft agar, and wound healing in a mouse lung adenocarcinoma cell line containing a constitutively active, mutant Kras. Similarly, modulation of VICKZ1 activity promotes or inhibits metastases upon implantation of these cells into syngeneic mice. To test these effects in a genetic model system, we generated a mouse with an inducible VICKZ1 transgene and found that isolated overexpression of VICKZ1 in the lungs had no noticeable effect on morphology. Although directed overexpression of mutant Kras in the lungs led to the formation of small adenomas, concurrent overexpression of VICKZ1 remarkably accelerated tumor growth and formation of pulmonary adenocarcinomas. VICKZ1-containing ribonucleoprotein complexes are highly enriched in Kras mRNA in lung adenocarcinoma cells, and Kras signaling is enhanced in these cells by overexpression of VICKZ1. Analysis of lung carcinoma patients reveals that elevated VICKZ1 expression correlates with lower overall survival; this reduction is dramatically enhanced in those patients bearing a mutant Kras gene. Our study reveals that RNA binding proteins of the VICKZ family can synergize with Kras to influence signaling and oncogenic activity.
- 30 January 2019
- Published by Springer Nature in Oncogene
- Vol. 38 (21) , 4169-4181
VICKZ1 enhances tumor progression and metastasis in lung adenocarcinomas in mice
The VICKZ (Igf2bp) family of RNA binding proteins regulate RNA function at many levels, including intracellular RNA localization, RNA stability, and translational control. One or more of the three VICKZ paralogs are upregulated in many different types of cancers. Here, we show how VICKZ1 enhances, and dominant negative VICKZ1 inhibits, cell migration, growth in soft agar, and wound healing in a mouse lung adenocarcinoma cell line containing a constitutively active, mutant Kras. Similarly, modulation of VICKZ1 activity promotes or inhibits metastases upon implantation of these cells into syngeneic mice. To test these effects in a genetic model system, we generated a mouse with an inducible VICKZ1 transgene and found that isolated overexpression of VICKZ1 in the lungs had no noticeable effect on morphology. Although directed overexpression of mutant Kras in the lungs led to the formation of small adenomas, concurrent overexpression of VICKZ1 remarkably accelerated tumor growth and formation of pulmonary adenocarcinomas. VICKZ1-containing ribonucleoprotein complexes are highly enriched in Kras mRNA in lung adenocarcinoma cells, and Kras signaling is enhanced in these cells by overexpression of VICKZ1. Analysis of lung carcinoma patients reveals that elevated VICKZ1 expression correlates with lower overall survival; this reduction is dramatically enhanced in those patients bearing a mutant Kras gene. Our study reveals that RNA binding proteins of the VICKZ family can synergize with Kras to influence signaling and oncogenic activity.
- Open Access
- 28 August 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (8) , e0136408
A Novel Role for VICKZ Proteins in Maintaining Epithelial Integrity during Embryogenesis
VICKZ (IGF2BP1,2,3/ZBP1/Vg1RBP/IMP1,2,3) proteins bind RNA and help regulate many RNA-mediated processes. In the midbrain region of early chick embryos, VICKZ is expressed in the neural folds and along the basal surface of the neural epithelium, but, upon neural tube closure, is down-regulated in prospective cranial neural crest (CNC) cells, concomitant with their emigration and epithelial-to-mesenchymal transition (EMT). Electroporation of constructs that modulate cVICKZ expression demonstrates that this down-regulation is both necessary and sufficient for CNC EMT. These results suggest that VICKZ down-regulation in CNC cell-autonomously promotes EMT and migration. Reduction of VICKZ throughout the embryo, however, inhibits CNC migration non-cell-autonomously, as judged by transplantation experiments in Xenopus embryos. Given the positive role reported for VICKZ proteins in promoting cell migration of chick embryo fibroblasts and many types of cancer cells, we have begun to look for specific mRNAs that could mediate context-specific differences. We report here that the laminin receptor, integrin alpha 6, is down-regulated in the dorsal neural tube when CNC cells emigrate, this process is mediated by cVICKZ, and integrin alpha 6 mRNA is found in VICKZ ribonucleoprotein complexes. Significantly, prolonged inhibition of cVICKZ in either the neural tube or the nascent dermomyotome sheet, which also dynamically expresses cVICKZ, induces disruption of these epithelia. These data point to a previously unreported role for VICKZ in maintaining epithelial integrity.
- 28 August 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (8) , e0136408
Open AccessA Novel Role for VICKZ Proteins in Maintaining Epithelial Integrity during Embryogenesis
VICKZ (IGF2BP1,2,3/ZBP1/Vg1RBP/IMP1,2,3) proteins bind RNA and help regulate many RNA-mediated processes. In the midbrain region of early chick embryos, VICKZ is expressed in the neural folds and along the basal surface of the neural epithelium, but, upon neural tube closure, is down-regulated in prospective cranial neural crest (CNC) cells, concomitant with their emigration and epithelial-to-mesenchymal transition (EMT). Electroporation of constructs that modulate cVICKZ expression demonstrates that this down-regulation is both necessary and sufficient for CNC EMT. These results suggest that VICKZ down-regulation in CNC cell-autonomously promotes EMT and migration. Reduction of VICKZ throughout the embryo, however, inhibits CNC migration non-cell-autonomously, as judged by transplantation experiments in Xenopus embryos. Given the positive role reported for VICKZ proteins in promoting cell migration of chick embryo fibroblasts and many types of cancer cells, we have begun to look for specific mRNAs that could mediate context-specific differences. We report here that the laminin receptor, integrin alpha 6, is down-regulated in the dorsal neural tube when CNC cells emigrate, this process is mediated by cVICKZ, and integrin alpha 6 mRNA is found in VICKZ ribonucleoprotein complexes. Significantly, prolonged inhibition of cVICKZ in either the neural tube or the nascent dermomyotome sheet, which also dynamically expresses cVICKZ, induces disruption of these epithelia. These data point to a previously unreported role for VICKZ in maintaining epithelial integrity.
- Open Access
- 15 May 2015
- Published by The Company of Biologists in Journal of Cell Science
- Vol. 128 (10) , 1922-1933
Localization of cofilin mRNA to the leading edge of migrating cells promotes directed cell migration
MRNA trafficking, which enables the localization of mRNAs to particular intracellular targets, occurs in a wide variety of cells. The importance of the resulting RNA distribution for cellular functions, however, has been difficult to assess. We have found that cofilin-1 mRNA is rapidly localized to the leading edge of human lung carcinoma cells and that VICKZ family RNA-binding proteins help mediate this localization through specific interactions with the 3′UTR of cofilin mRNA. Using a phagokinetic assay for cell motility, we have been able to quantify the effect of mRNA localization on the rescue of lung carcinoma cells in which cofilin was knocked down by using short hairpin RNA (shRNA). Although restoring cofilin protein to normal endogenous levels rescues general lamellipodia formation around the periphery of the cell, only when the rescuing cofilin mRNA can localize to the leading edge is it capable of also fully rescuing directed cell movement. These results demonstrate that localization of an mRNA can provide an additional level of regulation for the function of its protein product.
- 15 May 2015
- Published by The Company of Biologists in Journal of Cell Science
- Vol. 128 (10) , 1922-1933
Open AccessLocalization of cofilin mRNA to the leading edge of migrating cells promotes directed cell migration
MRNA trafficking, which enables the localization of mRNAs to particular intracellular targets, occurs in a wide variety of cells. The importance of the resulting RNA distribution for cellular functions, however, has been difficult to assess. We have found that cofilin-1 mRNA is rapidly localized to the leading edge of human lung carcinoma cells and that VICKZ family RNA-binding proteins help mediate this localization through specific interactions with the 3′UTR of cofilin mRNA. Using a phagokinetic assay for cell motility, we have been able to quantify the effect of mRNA localization on the rescue of lung carcinoma cells in which cofilin was knocked down by using short hairpin RNA (shRNA). Although restoring cofilin protein to normal endogenous levels rescues general lamellipodia formation around the periphery of the cell, only when the rescuing cofilin mRNA can localize to the leading edge is it capable of also fully rescuing directed cell movement. These results demonstrate that localization of an mRNA can provide an additional level of regulation for the function of its protein product.